Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Ziegler

Showing results (341-350 of 344) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 344 results.
Mayo Clinic Proceedings|February 13, 2007
Seroprevalence of antibody to varicella among Somali refugeesLana J Nysse, Norman A Pinsky, Jeffrey P Bratberg, et al.
Oecologia|March 18, 2017
Above-ground biomass and structure of pristine Siberian Scots pine forests as controlled by competition and fireC Wirth, E-D Schulze, W Schulze, et al.
The American Journal of Medicine|May 12, 2024
The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVIDHarlan M Krumholz, Mitsuaki Sawano, Bornali Bhattacharjee, et al.
The Lancet. Infectious Diseases|April 6, 2025
Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trialMitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, et al.
Pageof 35

Showing results (341-350 of 344) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 344 results.
Mayo Clinic Proceedings|February 13, 2007
Seroprevalence of antibody to varicella among Somali refugeesLana J Nysse, Norman A Pinsky, Jeffrey P Bratberg, et al.
Oecologia|March 18, 2017
Above-ground biomass and structure of pristine Siberian Scots pine forests as controlled by competition and fireC Wirth, E-D Schulze, W Schulze, et al.
The American Journal of Medicine|May 12, 2024
The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVIDHarlan M Krumholz, Mitsuaki Sawano, Bornali Bhattacharjee, et al.
The Lancet. Infectious Diseases|April 6, 2025
Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trialMitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, et al.
Pageof 35